Gilead Sciences, Inc. (NASDAQ:GILD) CFO Andrew D. Dickinson Sells 137,676 Shares of Stock

Gilead Sciences, Inc. (NASDAQ:GILD) CFO Andrew D. Dickinson sold 137,676 shares of Gilead Sciences stock in a transaction that occurred on Wednesday, February 12th. The stock was sold at an average price of $102.22, for a total transaction of $14,073,240.72. Following the completion of the sale, the chief financial officer now directly owns 171,223 shares of the company’s stock, valued at $17,502,415.06. The trade was a 44.57 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

Gilead Sciences Trading Up 2.6 %

NASDAQ GILD opened at $105.96 on Friday. The stock has a market cap of $132.05 billion, a P/E ratio of 1,177.33, a PEG ratio of 1.25 and a beta of 0.18. The company’s fifty day simple moving average is $93.38 and its 200-day simple moving average is $87.24. The company has a current ratio of 1.26, a quick ratio of 1.10 and a debt-to-equity ratio of 1.24. Gilead Sciences, Inc. has a 52 week low of $62.07 and a 52 week high of $106.43.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.90 EPS for the quarter, topping analysts’ consensus estimates of $1.67 by $0.23. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. Equities research analysts predict that Gilead Sciences, Inc. will post 4.35 EPS for the current fiscal year.

Gilead Sciences Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, March 28th. Investors of record on Friday, March 14th will be paid a $0.79 dividend. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.98%. The ex-dividend date is Friday, March 14th. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.77. Gilead Sciences’s payout ratio is 3,422.22%.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on GILD shares. Citigroup initiated coverage on Gilead Sciences in a research report on Thursday, November 14th. They issued a “buy” rating and a $125.00 price objective for the company. UBS Group lifted their price target on Gilead Sciences from $70.00 to $96.00 and gave the company a “neutral” rating in a report on Thursday, November 21st. Needham & Company LLC reiterated a “hold” rating on shares of Gilead Sciences in a report on Wednesday. Leerink Partnrs raised shares of Gilead Sciences from a “hold” rating to a “strong-buy” rating in a research report on Monday, October 21st. Finally, JPMorgan Chase & Co. upped their price target on shares of Gilead Sciences from $105.00 to $115.00 and gave the stock an “overweight” rating in a research report on Wednesday, January 29th. Eleven research analysts have rated the stock with a hold rating, fourteen have issued a buy rating and four have assigned a strong buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $101.33.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the stock. HHM Wealth Advisors LLC raised its stake in shares of Gilead Sciences by 118.5% in the 4th quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 154 shares in the last quarter. nVerses Capital LLC acquired a new position in Gilead Sciences in the third quarter worth about $25,000. YANKCOM Partnership bought a new stake in Gilead Sciences in the fourth quarter valued at about $28,000. Decker Retirement Planning Inc. acquired a new stake in Gilead Sciences during the fourth quarter valued at approximately $29,000. Finally, Valued Wealth Advisors LLC lifted its holdings in Gilead Sciences by 101.9% during the 3rd quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company’s stock worth $27,000 after buying an additional 161 shares during the last quarter. 83.67% of the stock is currently owned by institutional investors.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.